MEANING OF NANOPARTICIPANTS IN INTERFERON TRANSPORT
DOI:
https://doi.org/10.31548/dopovidi2018.01.005Keywords:
nanotechnology, interferon, nanoparticles, nanocomplexAbstract
The article analyzes the materials of scientific works on the preparation and use of preparations containing interferon and nanoparticles of metals or proteins. The application of a new innovative nanotechnology method using nanoparticles provides broad opportunities for improving the targeted delivery of drugs to the pathological process, implementing an optimal toxicity profile.
The purpose of our work was to conduct an analysis of scientific works on the introduction into the medical practice of interferon complexes with nanoparticles of metals or proteins, to identify their advantage and provide a characteristic.
It has been established that the nanocomplex obtained can enhance the effectiveness of interferon, reduce its side effects and have controlled release of the drug in the body. Among the antiviral nano-drugs, are actively involved in medical practice - interferon and its derivatives. The system of interferon is on the first line of protection of the organism from infection. Interferon acts on all viruses that enter the body.
Taking into account the viral nature of some types of cancer, the interest in using IFN drugs in oncology has increased significantly after their high antiviral activity has been shown.
Positive results have been found in the use of IFN in the treatment of chronic hepatitis B and C, condylomatosis and several tumor-like neoplasms, for example, AIDS-related measles, chronic myeloid leukemia, follicular lymphoma, T-cell lymphoma, carcinoma of the tumor, melanoma, and numerous renal cell carcinomas.
Employees of the DNU ("State Center for Innovative Biotechnologies") are developing a new preparation of recombinant human interferon with low-dose cerium dioxide. The main purpose relied on this drug - the fight against viral infection and prolonged antitumor action. The named complex successfully runs preclinical and clinical studies. According to the results of experiments in vivo, scientists were able to prolong the action of interferon ox 2 to 5 days. The anti-herpetic activity of cerium dioxide nanoparticles on the model of genital herpes in cavy has been investigated. Numerous experiments indicated the prophylactic and therapeutic efficacy of the use of a complex of cerium dioxide and interferon nanoparticles in a concentration of 1.25 mM
In the future, the continuation of work on the creation of a new pharmaceutical drug based on interferon and nanoparticles of the metal to optimize its effectiveness and reduce side effects.
References
Chekman, I. S., Pryskoka, (2010). Nanotekhnolohii u rozrobtsi system dostavky likarskykh zasobiv [Nanotechnology in the development of drug delivery systems]. Ukrainskyi medychnyi chasopys, 1(75), 14-18.
Rozenfeld, L. H., Moskalenko, V. F., Chekman, I. S., Movchyn, B. O. (2008). Nanotekhnolohii, Nanomedytsyna: Perspektyvy naukovykh doslidzhen ta vprovadzhennia yikh rezultativ u medychnu praktyku [Nanotechnology, Nanomedicine: Prospects for research and implementation of their results in medical practice]. Ukrainskyi medychnyi chasopys, 5 (67), 63-68.
Isaacs, A., Lindenmann, J. (1957). Virus interference. I. The interferon. Proceedings of the royal society, Ser. B, 147, 258-267.
https://doi.org/10.1098/rspb.1957.0048
Interferon nomenclature. (1983). Archives of Virology, 77, 2, 4, 283-285.
https://doi.org/10.1007/BF01309277
Pestka, S., Krause, C. D., Walte, M. R. (2004). Interferons, interferon-like cytokines, and their receptors, Immunological Reviews, 202, 8-32.
https://doi.org/10.1111/j.0105-2896.2004.00204.x
Brayfield, A. (2014). Martindale: The Complete Drug Reference. London:Pharmaceutical Press. http://www.medicinescomplete.com.
Oksamytnyi, V. M. (2015). Interferony. Problemy infektsiinykh khvorob tvaryn. [Interferons Problems of infectious animal diseases]. Nizhyn, 487-505.
Oksamytnyi, V. M., Zholobak, N. M., Tymoshok, N. O. Shcherbakov, A. B., Rybalko, S. L., Synytsyn, V. A. , Volkov, M. V., Spivak, M. Ia., Shevchuk, V. O. (2014). Interferon ta nanochastynky dioksydu tseriiu yak osnova stvorennia antyvirusnoho preparatu [Interferon and cerium dioxide nanoparticles as the basis for antiviral drug]. Veterynarna biotekhnolohiia, Nizhyn, 24, 146-154.
Feczkó, T., Fodor-Kardos, A., Sivakumaran, M., Shubhra, Q. T. H. In-vitro interferon- α release from interferon- α and pegylated IFN- α loaded PLGA and PEG-PLGA nanoparticles. Available at: ttp://real.mtak.hu/44974/1/Feczko_et_al_2016_In_vitro_IFN_alpha_REAL_u.pdf.
Kuo, H. P., Goh, L. L., Lu, M. W., Kong, Z. L. (2016). Delivery of grouper Interferon by chitosan-modified poly (lactic-co-glycolic acid) nanoparticles to protect nervous necrosis virus infection. Source: Journal of Nanoscience and Nanotechnology, 16, 7, 7521-7529.
https://doi.org/10.1166/jnn.2016.12348
Yang, J. A., Park, K., Jung, H., Kim, H, Hong, S. W., Yoon, S. K., Hahn, S. K. Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis C virus infection. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21872329.
Min-Young, L., Jeong-A, Y., Ho Sang, J., Songeun, B., Jung Eun, C., Wonhee, H., Heebeom, K., Kwangmeyung, K., Seung Kew, Y., Sei Kwang, H. Hyaluronic acid gold nanoparticle. Interferon R complex for targeted treatment of hepatitis C virus infection available at: http://pubs.acs.org/doi/abs/10.1021/nn302538y.
Giri, N., Tomar, P., Karwasara, V. S., Pandey, R. S., Dixi, V. K., Targeted novel surface-modified nanoparticles for interferon delivery for the treatment of hepatitis B. Available at: http://oaji.net/articles/2016/3004-1455527068.pdf.
Mohseni, N., Sarvestani, F. S., Ardestani, M. S., Kazemi-Lomedasht, F. N. Inhibitory effect of gold nanoparticles conjugated with interferon gamma and methionine on breast cancer cell line. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21914636.
Segura, S., Gamazo, C., Irache, M. J., Spuelas, S. Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against brucella abortus. Available at:
https://doi.org/10.1128/AAC.00890-06
Ivanov, V., Zholobak N., Shcherbakov A. Oksid tseriya povyshayet effektivnost' vaktsin protiv grippa [Cerium oxide improves the effectiveness of influenza vaccines]. Available at: https://www. kommersant.ru/doc/3212072.
Ushkalov, V. O., Machuskyi, O. V, Romanko, M. Ie., Hruzina, T. H, Rieznichenko, L. S., Koshelnyk, V. H, Yakovlieva L. M. (2011). Rezultaty komisiinykh doslidzhen vaktsyny proty sybirky tvaryn iz shtamu Bacillus anthracis Sterne 34 F2 [Results of commision research on anthrax vaccine of Bacillus anthracis Sterne 34 F2 strains]. Naukovyi visnyk veterynarnoi medytsyny, Bila Tserkva, 7 (83). 102-109.
Kontseptsiia rozrobky ta vykorystannia kompleksnykh dezinfektantiv dlia veterynarnoi medytsyny (2011) [Concept of development and use of complex disinfectants for veterinary medicine: Monograph]. K., NUBiP Ukrainy, 146.
Reznichenko, L. S., Dybkova, S. M., Ryzhenko, V. P., Nychyk, S. A., Ryzhenko, H. F., Horbatiuk, I. O. Andriiashchuk, V. O. (2014). Biotekhnolohiia nanovaktsyn. Elektronno-mikroskopichni doslidzhennia kontaktnoi vzaiemodii nanochastynok sribla z mikroorhanizmamy [Biotechnology nano-vaccine. Electron microscopic studies of contact interaction of silver nanoparticles with microorganisms]. Veterynarna biotekhnolohiia, Nizhyn, 24, 184-189.
Downloads
Published
Issue
Section
License
Relationship between right holders and users shall be governed by the terms of the license Creative Commons Attribution – non-commercial – Distribution On Same Conditions 4.0 international (CC BY-NC-SA 4.0):https://creativecommons.org/licenses/by-nc-sa/4.0/deed.uk
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
